Pfizer Inc. or Amgen Inc.: Who Invests More in Innovation?

Pfizer's R&D spending nearly doubles Amgen's over a decade.

__timestamp	Amgen Inc.	Pfizer Inc.
Wednesday, January 1, 2014	4297000000	8393000000
Thursday, January 1, 2015	4070000000	7690000000
Friday, January 1, 2016	3840000000	7872000000
Sunday, January 1, 2017	3562000000	7657000000
Monday, January 1, 2018	3737000000	8006000000
Tuesday, January 1, 2019	4116000000	8650000000
Wednesday, January 1, 2020	4207000000	9405000000
Friday, January 1, 2021	4819000000	13829000000
Saturday, January 1, 2022	4434000000	11428000000
Sunday, January 1, 2023	4784000000	10679000000
Monday, January 1, 2024	5964000000	10930000000

Unveiling the hidden dimensions of data

Innovation Investment: Pfizer vs. Amgen

In the competitive landscape of pharmaceuticals, innovation is key. Over the past decade, Pfizer Inc. and Amgen Inc. have been at the forefront, investing heavily in research and development (R&D). From 2014 to 2023, Pfizer consistently outpaced Amgen, with R&D expenses peaking in 2021 at approximately 13.8 billion dollars, nearly double Amgen's highest expenditure of around 4.8 billion dollars in the same year. This trend highlights Pfizer's aggressive strategy in innovation, especially during the pandemic years, where their R&D spending surged by over 80% from 2014. Meanwhile, Amgen's investment grew more modestly, reflecting a steady commitment to innovation. As the pharmaceutical industry evolves, these investments underscore the critical role of R&D in driving future breakthroughs and maintaining competitive advantage.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025